Benzinga | Mar 25, 2021 08:25AM EDT

B. Riley FBR Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $60

B. Riley FBR analyst Justin Walsh initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Buy rating and announces Price Target of $60.